Marc Martinell

Marc Martinell has a strong background in the biotech industry with experience in various roles and companies. Marc is the Co-founder & CEO of Minoryx Therapeutics, a biotech company focused on developing therapies for orphan CNS diseases. Marc has been involved in the development of their lead program, leriglitazone.

Before Minoryx Therapeutics, Marc worked at Oryzon Genomics as the Head of Project Generation. There, they managed a multidisciplinary team and was responsible for various aspects of drug development, including target identification, assay development, protein production, and mechanism-of-action studies.

Prior to Oryzon Genomics, Marc was the Head of Biophysics at Crystax Pharmaceuticals. Marc led the fragment-based approach and the development of new assays, with a focus on biophysics-based methods. Marc also managed discovery projects and collaborated with other pharmaceutical companies within the GENIUS Pharma consortium.

Marc has also worked as a Pre-doctoral researcher at Institut Recerca Biomèdica (IRB) and University of Barcelona. At IRB, they conducted research as part of their doctoral studies.

Additionally, Marc has served as a Board Member at CataloniaBIO.

Overall, Marc Martinell has extensive experience in the biotech industry, particularly in drug discovery and development.

Marc Martinell has a diverse educational background. From 1995 to 1999, they attended Universitat de Barcelona, where they obtained a Bachelor's degree in Chemistry. Marc then proceeded to pursue further academic studies at the same university and obtained a PhD in Molecular Recognition from 1999 to 2004. In 2007, Marc participated in the Ignite training program for entrepreneurs at CfEL, Judge Business School, University of Cambridge. In 2011, they attended Bioemprenedor XXI, although details regarding the degree or field of study for this particular program are not provided.